Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant epstein-barr virus vaccine
- Development stage
- Unknown
- Lead developer
- ModeX Therapeutics
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Recombinant Epstein-Barr Virus Vaccine refers to a class of investigational vaccines designed to prevent or treat infection by the Epstein-Barr virus (EBV), a member of the herpesvirus family that is associated with infectious mononucleosis and several cancers (including nasopharyngeal carcinoma, natural killer T-cell lymphoma, gastric cancer) as well as autoimmune diseases such as multiple sclerosis. These vaccines use recombinant technology to express key EBV antigens—such as gp350, gH/gL/gp42—either via mRNA platforms or nanoparticle display systems. The leading candidates include MDX2201 (developed by ModeX Therapeutics/OPKO Health in collaboration with Merck), which uses a ferritin nanoparticle platform displaying four viral proteins involved in host cell entry to stimulate broad protective immunity against both B cell and epithelial cell infection[2][3][6]. Another candidate is WGc-043 (developed by WestGene Biopharma), an mRNA-based therapeutic cancer vaccine targeting EBV-related malignancies[1][4][5]. As of June 2025, no recombinant EBV vaccines are approved for use; all are in early clinical development.
- Other names
- ebv vaccinerecombinant ebv vaccinemdx2201mdx-2201mdx 2201wgc-043wgc043wgc 043
02
Targets
EBV gH/gL (Epstein-Barr virus glycoprotein H/glycoprotein L complex)gp350 (Epstein-Barr virus glycoprotein 350)gp42 (Epstein-Barr virus glycoprotein 42)GH (Growth hormone)gL (Epstein-Barr virus glycoprotein L)
Beyond the preview
Go deeper on recombinant epstein-barr virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant epstein-barr virus vaccine.